KontRASt-01: Preliminary Safety and Efficacy of JDQ443+TNO155 in Patients with Advanced, KRAS G12C-Mutated Solid Tumors

被引：0

作者：

Negrao, M. V. ^{[1
]}

Cassier, P. A. ^{[2
]}

Solomon, B. ^{[3
]}

Schuler, M. ^{[4
]}

Rohrberg, K. ^{[5
]}

Cresta, S. ^{[6
]}

Dooms, C. ^{[7
,8
]}

Tan, D. S. W. ^{[9
]}

Loong, H. H-F. ^{[10
]}

Amatu, A. ^{[11
]}

Assmann, K. Krueger ^{[12
]}

Fairchild, L.

Sansregret, L. ^{[13
,14
]}

Fan, L.

Farago, A. F. ^{[13
]}

Cho, B. C. ^{[15
]}

机构：

[1] MD Anderson Canc Ctr, Houston, TX USA

[2] Ctr Leon Berard, Lyon, France

[3] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[4] Univ Hosp Essen, West German Canc Ctr, Essen, Germany

[5] Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark

[6] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[7] Univ Hosp Gasthuisberg, Leuven, Belgium

[8] Katholieke Univ Leuven, Leuven, Belgium

[9] Natl Canc Ctr Singapore, Duke NUS Med Sch, Singapore, Singapore

[10] Chinese Univ Hong Kong, Hong Kong, Peoples R China

[11] Niguarda Canc Ctr, Grande Osped Metropolitano Niguarda, Milan, Italy

[12] Novartis Inst BioMed Res, E Hanover, NJ USA

[13] Novartis Inst BioMed Res, Cambridge, MA USA

[14] Novartis Inst BioMed Res, Basel, Switzerland

[15] Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea

来源：

JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期

关键词：

Solid tumors; KRASG12C inhibitor; Phase I; NSCLC;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA06.03

引用

页码：S117 / S118

页数：2

共 50 条

[1] KontRASt-01 Update: Safety and Efficacy of JDQ443 in KRAS G12C-Mutated Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC)
Cassier, P.
Dooms, C.
Gazzah, A.
Felip, E.
Steeghs, N.
Rohrberg, K. S.
De Braud, F.
Solomon, B.
Schuler, M.
Tan, D. S.
Yamamoto, N.
Loong, H. H. F.
Cho, B. C.
Wolf, J.
Lin, C. C.
Negrao, M. V.
Werner, L.
Cui, X.
Farago, A. F.
DeMiguel, M. J.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (01): : E4 - E5
[2] KontRASt-01 update: safety and efficacy of JDQ443 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC)
Schuler, M.
Cassier, P. A.
Dooms, C.
Gazzah, A.
Felip, E.
Steeghs, N.
Rohrberg, K. S.
De Braud, F.
Solomon, B.
Tan, D. S.
Yamamoto, N.
Loong, H. H.
Cho, B. C.
Wolf, J.
Lin, C. -C
Negrao, M.
Werner, L.
Cui, X.
Farago, A. F.
de Miguel, M. J.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 147 - 148
[3] KontRASt-01 update: Safety and efficacy of JDQ443 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC)
Cassier, Philippe Alexandre
Dooms, Christophe Alfons
Gazzah, Anas
Felip, Enriqueta
Steeghs, Neeltje
Rohrberg, Kristoffer Staal
De Braud, Filippo G.
Solomon, Benjamin J.
Schuler, Martin H.
Tan, Daniel Shao-Weng
Yamamoto, Noboru
Loong, Herbert H. F.
Cho, Byoung Chul
Wolf, Juergen
Lin, Chia-Chi
Negrao, Marcelo Vailati
Werner, Lillian
Cui, Xiaoming
Farago, Anna F.
de Miguel, Maria J.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[4] KontRASt-01: A Phase Ib/II Dose Escalation Study of JDQ443 in Patients with advanced KRAS G12C mutated solid Tumors
Schuler, M.
Tan, D. S.
Shimizu, T.
Solomon, B.
Heist, R. S.
de Miguel, M.
Gazzah, A.
Wermke, M.
Dooms, C.
Loong, H. H.
Steeghs, N.
Felip, E.
Steuer, C. E.
Van Cutsem, E.
Soo, R. A.
Jaeger, A.
Kim, J.
Xu, K.
Cui, X.
Burks, H.
Farago, A. F.
Cassier, P. A.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 29 - 29
[5] KontRASt-02: A phase III trial investigating the efficacy and safety of the KRASG12C inhibitor JDQ443 vs docetaxel in patients with previously treated, locally advanced or metastatic, KRAS G12C-mutated NSCLC.
Cappuzzo, Federico
Castro, Gilberto
Kang, Jin-Hyoung
Wu, Yi-Long
Brustugun, Odd Terje
Cheema, Parneet Kaur
Owonikoko, Taofeek K.
Longin, Anne-Sophie
Boran, Aislyn
Duan, Jiawei
Caparica, Rafael
Loong, Herbert H. F.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[6] KontRASt-02: A Phase III Trial Investigating the Efficacy and Safety of the KRASG12C Inhibitor JDQ443 vs. Docetaxel in Patients with Previously Treated, Locally Advanced or Metastatic, KRAS G12C-Mutated NSCLC
Cappuzzo, F.
Castro Junior, G.
Kang, J. H.
Wu, Y. L.
Brustugun, O. T.
Cheema, P. K.
Owonikoko, T. K.
Longin, A. S.
Duan, J.
Caparica, R.
Loong, H. H. F.
Chan, E.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (01): : E14 - E14
[7] Assessing the safety profile of sotorasib in KRAS G12C-mutated advanced NSCLC
Reactions Weekly, 2025, 2045 (1) : 6 - 6
[8] CodeBreaK 101: Safety and Efficacy of Sotorasib with Carboplatin and Pemetrexed in KRAS G12C-Mutated Advanced NSCLC
Clarke, J. M.
Felip, E.
Li, B. T.
Ruffinelli, J. C.
Garrido, P.
Zugazagoitia, J.
Goldberg, S. B.
Ramalingam, S. S.
Victoria, I.
Puri, S.
Gandara, D. R.
Varrieur, T.
Edmonds, S.
Palmer, K.
Snyder, W.
Govindan, R.
Rybkin, I.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S118 - S119
[9] KontRASt: A Phase Ib/II, open-label, multi-center, dose-escalation study of JDQ443 in patients with advanced solid tumors harboring the KRAS G12C mutation
Solomon, Benjamin
Heist, Rebecca S.
Tan, Daniel S. W.
Cassier, Philippe A.
Dooms, Christophe
Van Cutsem, Eric
Steuer, Conor E.
Steeghs, Neeltje
Schuler, Martin
Gazzah, Anas
Wermke, Martin
Felip, Enriqueta
Loong, Herbert H. F.
Luken, Maria J. De Miguel
Soo, Ross A.
Jaeger, Ashley
Xu, Kun
Chen, Xueying
Cui, Xiaoming
Burks, Heather
Farago, Anna F.
Shimizu, Toshio
MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
[10] Efficacy and safety outcomes in patients receiving sotorasib for advanced KRAS G12C-mutated non-small cell lung cancer
Milner-Watts, Charlotte
O'Sullivan, Hazel
Stewart, James
Idaikkadar, Praveena
Tokaca, Nadza
Davidson, Michael
Yousaf, Nadia
Bhosle, Jaishree
Popat, Sanjay
O'Brien, Mary
Minchom, Anna
LUNG CANCER, 2023, 178 : S31 - S32

← 1 2 3 4 5 →